Funder: Dept. of the Army -- USAMRAA
Due Dates: June 24, 2026: Pre-Application (Preproposal) | September 30, 2026: Full Application
Funding Amounts: ~$12M total; up to $2M per award (max 3 years); ~6 awards expected
Summary: Supports preclinical to IND-enabling therapeutic development for ALS, with required biomarker integration.
Key Information: IND-approved therapeutics are NOT eligible; lead compound and proof-of-concept data required.